An open label Phase 1 study to assess central D2/D3 Receptor occupancy using Positron emission Tomography (PET) following multiple oral dose administration of PF-00217830 in the healthy adult
PI
Pfizer
Havard, Patty
PCN Pharmacokinetic Study
PI
Harvard Medical Faculty Physicians
Morse, Gene
Ryan White Title III
PI
Health Resources And Services Administration
Morse, Gene
NYSDOH Adherence
PI
New York State Department of Health
Morse, Gene
Opiods and HIV Medications; Interactions in Drug Abusers
PI
Virginia Commonwealth University- Subcontract From National Institute On Drug Abuse
Morse, Gene
Adult Therapeutic Clinical Trials Program for AIDS
PI
University Of Rochester
Morse, Gene
TDM & Drug Interactions in HIV Infected Substance Abusers
PI
National Institute On Drug Abuse
Morse, Gene
AACTG Pharmacology Support Laboratory
PI
National Institute of Allergy and Infectious Diseases
Morse, Gene
AACTG Pharmacology Support Laboratory QA/QC
PI
National Institute of Allergy and Infectious Diseases
Morse, Gene
ACTG-5146 Laboratory Services
PI
Virco
Tornatore, Kathleen
The Relationship of Drug Exposure Immunodynamic Response During Myfortic Therapy in Stable African American and Caucasian Renal Transplant Recipients
PI
Novartis
FY 05-06
Faculty Member
Grant Title
Role (PI or CoI)
Sponsor
Bednarczyk, Edward
Central D2 Receptor Occupancy in Schizophrenia Patients following Multiple Oral Doses of CP-903,397 Using [11C] Raclopride -Protocol #5401003
PI
Pfizer
Dicenzo, Robert
Optimizing Adjuvant Chemotherapy in Obese and Overweight Women
PI
American College of Clinical Pharmacy
Dicenzo, Robert
Pharmacokinetics of Lopinavir in Plasma and CSF of HIV Infected Adults
PI
University of Rochester
Haas, Curtis
Kinetics and Dynamics of IV Enoxaparin in the Trauma ICU
PI
American College of Clinical Pharmacy
Haas, Curtis
Collaborative program in pharmacotherapy research, practice and clinical education relative to critically ill patients
PI
University of Rochester
Morse, Gene
Ryan White Title III
PI
Health Resources & Services Administration
Morse, Gene
NYSDOH Adherence
PI
New York State Department of Health
Morse, Gene
Opiods and HIV Medications; Interactions in Drug Abusers
PI
Virginia Commonwealth University – Subcontract From National Institute on Drug Abuse
Morse, Gene
Adult Therapeutic Clinical Trials Program for AIDS
PI
University of Rochester
Morse, Gene
TDM & Drug Interactions in HIV Infected Substance Abusers
PI
National Institute on Drug Abuse
Morse, Gene
Drug Interactions and Antiretrovirals in Resource Poor Countries (International Supplement)
PI
National Institute on Drug Abuse
Morse, Gene
Drug Interaction Studies of Buprenorphine (Administrative Supplement)
PI
National Institute on Drug Abuse
Morse, Gene
TDM and Drug Interactions in HIV Infected Substance Abusers
PI
National Institute on Drug Abuse
Morse, Gene
Summer Research with NATIONAL INSTITUTE ON DRUG ABUSE
PI
National Institute on Drug Abuse
Morse, Gene
AACTG Pharmacology Support Laboratory
PI
National Institute of Allergy and Infectious Diseases
Morse, Gene
AACTG Pharmacology Support Laboratory QA/QC
PI
National Institute of Allergy and Infectious Diseases
Morse, Gene
ACTG-5146 Laboratory Services
PI
Virco
Morse, Gene
Evaluation of Patient-Centered Pharmacotherapy Management
PI
Multi-Sources
Morse, Gene
Contemporary Practices of Pharmacists & Pharmacy Technicians
PI
American College of Clinical Pharmacy
Schroeder, Walt
Assessment of Eptifatide Dosing in Patients with Renal Dysfunction
PI
University of Massachusetts
Smith, Patrick
A Phase I, Open-Label, 2-Period, Single Sequence, Drug Interaction Study to Assess Steady-State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD with Fosamprena
PI
GlaxoSmithKline
Smith, Patrick
The Effect of Co-Administration of "Boosted" Saquinavir and Methodone on the PK
PI
Hoffman Laroche
Tsuji, Brian
Optimizing Antibiotic Dosing in Staphyloccus aureus Bloodstream Infection
PI
Interdisciplinary Research Development Fund
FY 04-05
Faculty Member
Grant Title and grant number
Role (PI, co-PI, contractor, consultant, etc.)
Sponsor
Ed Bednarczyk
Coenzyme CoQ10 Bioequivalence Study, 9103-524835,
PI
Pfizer
Ed Bednarczyk
IPA for Ellana Eberhardt, 1044868-1-34952,
PI
Western New York Veterans Administration
Ed Bednarczyk
Assessment of central mu opiate receptor occupancy after single doses of CP-866087 using positron emissiontomography (PET) in healthy adult subjects, 9103-545835
PI
Pfizer
Gayle Brazeau
Evaluation of Tissue Damage of Test Formulations, 1044065-1-34565
PI
Novartis
Gayle Brazeau
Formulation and Particle Size Effects on Toleration of Intramuscular Formulations, 1045054-1-35047
PI
Pfizer
Curtis Haas
Collaborative Program in Pharmacotherapy Research, Practice and Clinical Education Relative to Critically Ill Patients, 1042530-1-33754
PI
University Of Rochester
Curtis Haas
Clinical Study No. A3381009, 9103-524235
PI
Pfizer
Gene Morse
Opioids & HIV Medications Interactions in Drug Abusers, 1045067-1-35053
PI
Virginia Commonwealth University-Subcontract From National Institute On Drug Abuse
Gene Morse
Targeted Neuroprotection 1021524-1-23776
PI
University Of Rochester
Gene Morse
Adult Therapeutic Clinical Trials Program for Aids, 1045185-1-35116
PI
University Of Rochester
Gene Morse
AACTG Pharmacology Support Laboratory, 1045100-1-35067
PI
National Institute of Allergy and Infectious Diseases
Gene Morse
AACTG-QA/QC, 1048689-1-36576
PI
National Institute of Allergy and Infectious Diseases
Gene Morse
TDM & Drug Interactions in HIV Infected Substance Abusers, 1033722-1-29328, Subawards: University of Rochester , U of Miami , Montefiore Medical Ctr, Case Western
PI- Morse Co-I Forrest Co-I Brazeau, D.
National Institute On Drug Abuse
Gene Morse
Drug Interactions & Antiretroviral in Resource Poor Countries, 1048666-1-29328 Subaward: Zimbabwe
PI
National Institute On Drug Abuse
Gene Morse
ACTG-5146, 9103-522735
PI
Virco Labs
Gene Morse
Ryan White Title III, 1018487-1-22091
PI
Health Resources & Services Administration
Gene Morse
NYSDOH Adherence, 1018487-1-22091
PI
Heath Resources & Services Administration
Judianne Slish
Longitudinal Assessment of Protease Inhibitors in HIV/HCV/HBV Co-Infected Patients, 9103-548235
PI
Pfizer
Patrick Smith
Pharmacotherapy Residency in Oncology, 9103-536935
PI
Amgen
Patrick Smith
Human Serum on In Vitro Antibacterial Potency of Televancin, 9103-547435
PI
Theravance
Tornatore, Kathleen
Relationship of 2 Hr Cyclosporine Concentration Study, 9103-518135